Virbac SA
V16
Company Profile
Business description
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
Contact
13e rue
1ere avenue 2065, LID - BP 27
Carros06511
FRAT: +33 492087100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
50
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,372.28 | 0.00 | 0.00% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,947.25 | 235.60 | 0.46% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 24,975.82 | 161.87 | -0.64% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,411.98 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |